Free-text search
Content Types
-
Pfizer wins new FDA approval for Tukysa in breast cancer
Pfizer is strengthening its position in HER2-positive breast cancer. The FDA has approved Tukysa as a first-line maintenance treatment after a phase III trial s...
-
A new name for a broader outlook
Life science is, by its very nature, an international industry. Companies, research and people move across borders – and anyone covering the sector needs to do the same.
-
Elicera reports strong CAR‑T-Data – shares rise
The Swedish CAR‑T developer Elicera saw its share price surge following an update on the company’s ongoing lymphoma study.
-
Denmark a leader in EU clinical trials: “We should never accept unnecessary delays”
A principal of quick processing as well as engaging in ongoing dialogue with sponsors has helped Denmark to lead EU in clinical trials.
-
Getinge aims to expand in transplantation – with an eye on China
The Swedish medtech company Getinge plans to expand within organ transplantation in Europe and Asia, says CEO Mattias Perjos.
-
Novartis expands brain‑delivery push with Sironax deal
Novartis continues to invest in new methods for the efficient delivery of medicines to the brain.
-
FDA clears 3.95 million dollar gene therapy
For the first time, there is now an approved gene therapy for Sanfilippo syndrome type A. The disease is extremely rare, and the treatment is among the most exp...
-
The newborn injection more parents are choosing to decline
A vitamin K injection has long been routine for newborn babies, protecting them against rare but potentially serious bleeding. But in the US, a growing number o...
-
Novonesis to invest €600 million in India factory
Danish biosolutions manufacturer Novonesis has decided to invest massively in its Indian factory.
-
Anocca doses first Swedish patient with its TCR-T therapy
Five patients have so far been treated with Anocca’s in-house developed TCR-T cell therapy candidate for pancreatic cancer, with the latest becoming the first p...
-
ZEISS elevates ophthalmic workflows at ESCRS with new surgical and digital advancements
ZEISS Medical Technology will showcase its latest portfolio advancements and workflow enhancements for cataract, corneal refractive, and retina, at the European...
-
FDA approves first SMA therapy targeting muscle loss
A new type of medication for the rare genetic disease spinal muscular atrophy (SMA) has been approved in the United States.
-
GSK to close German vaccine plant – 641 jobs at risk
Demand for traditional flu vaccines is declining. GSK is now consolidating production in Canada and closing its plant in Dresden, putting 641 jobs at risk.
-
“Not the results we hoped for” – Novartis’ heart study shows no benefit
Novartis’ drug candidate pelacarsen, aimed at a well‑known cardiovascular risk factor, failed to reduce the risk of heart attack, stroke and cardiovascular deat...
-
David Lang on the future of robotic surgery: More people should gain access
David Lang, Head of the Nordic Region at robotic surgery company Intuitive, delivers the opening address at Medtechdagen 2026 next week. On stage, he will discu...
-
Gold Rush in Oral Peptides: “Everybody Wants In”
After Ozempic, pharmaceutical companies are racing toward the next big revolution: peptides that can be swallowed as easily as they can be injected. Cyprumed is...
-
Lithuania accelerates life science ambitions with major cell therapy investment
A new center for cell therapy and personalized medicines has opened in the Lithuanian capital, Vilnius.
-
Tandem Health raises $100m to expand in Europe
Swedish AI company Tandem Health has raised $100m. The funding will be used to strengthen the company’s position in Europe.
-
Introducing ZEISS VersaXRM 5 Insight
Stay in the flow from overview to insight.
-
Sanofi Sweden: ”We will work for more clinical trials”
Sanofi Sweden may represent only a modest share of the global Sanofi group, which employs nearly 80,000 people, but it still makes a significant research impact...
-
U.S. patent clears path for Elicera’s glioblastoma CAR‑T
Elicera Therapeutics announced on Friday that the company has received advance notice of the approval of a U.S. patent related to its CAR‑T cell candidate ELC‑401.
-
Leqembi Iqlik launches as start‑dose option
The Alzheimer’s drug Leqembi, discovered by the Swedish company BioArctic and developed by Eisai, has now been launched in the United States as a subcutaneous t...
-
Dialysis company hit with $15M bill after massive patient data breach
A cyberattack last year exposed the personal data of millions of patients at dialysis provider DaVita. Now the bill has arrived for the company: 15 million dollars in damages.
-
AstraZeneca combination shows promise in advanced lung cancer
AstraZeneca and China's Hutchmed have reported positive phase III results for a combination of their cancer drugs Tagrisso and Orpathys in advanced lung cancer.
BREAKING